KRAS and adenocarcinoma: KRAS is the most common driver mutation in patients with NSCLC, occurring in 30% to 40% of all NSCLC adenocarcinomas in western populations.1, 2, 3, 4 Through downstream signaling, mutations in KRAS can lead to uncontrolled cell growth and proliferation.1